Skip to content

Study · Observational study · n = 97 · 1993

4 results

Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome.

Homburg R, Levy T, Berkovitz D, Farchi J, Feldberg D, Ashkenazi J, Ben-Rafael Z

Fertility and sterility1 Mar 1993Cited by 68 (Europe PMC)

PMID8458452 (opens in a new tab)DOI10.1016/s0015-0282(16)55794-x (opens in a new tab)PepBankPUB-08458452
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In women with PCOS, added triptorelin was linked to fewer miscarriages across achieved pregnancies than gonadotropins alone.

    In plain wordsIn women with PCOS, added triptorelin was linked to fewer miscarriages across achieved pregnancies than gonadotropins alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePooled miscarriage rate
    Study

    n = 97

    Comparator
    Gonadotropins alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg single doseAs given in this study (human).

    Measurements

    Miscarriage rate
    17.6%
    with GnRH agonist
    Miscarriage rate
    39.1%
    gonadotropins alone

    Source sentences

    Summary
    Of pregnancies achieved with GnRH-a, 17.6% miscarried compared with 39.1% of those achieved with gonadotropins alone.
    2 context sentences
    Summary · context
    Retrospective analysis of the outcome of 97 pregnancies according to the treatment protocol, with or without GnRH-a.
    Summary · context
    Gonadotropin-releasing hormone agonist (Decapeptyl, D-Trp6, microcapsules, 3.75 mg) was given in a single dose 2 weeks before gonadotropin treatment.
  2. 02HumanObservational studyEfficacy outcome

    In women with PCOS, added triptorelin was linked to fewer miscarriages after ovulation induction than gonadotropins alone.

    In plain wordsIn women with PCOS, added triptorelin was linked to fewer miscarriages after ovulation induction than gonadotropins alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseMiscarriage after ovulation induction
    Study

    n: not reported in source

    Comparator
    Gonadotropins alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg single doseAs given in this study (human).

    Measurements

    Miscarriage rate
    16.7%
    with GnRH agonist
    Miscarriage rate
    39.4%
    without GnRH agonist

    Source sentences

    Summary
    Miscarriage rates after treatment in ovulation induction with (16.7%) and without GnRH-a (39.4%) and in IVF with (18.2%) and without GnRH-a (38.5%) were almost identical and were therefore analyzed together.
    2 context sentences
    Summary · context
    Retrospective analysis of the outcome of 97 pregnancies according to the treatment protocol, with or without GnRH-a.
    Summary · context
    Gonadotropin-releasing hormone agonist (Decapeptyl, D-Trp6, microcapsules, 3.75 mg) was given in a single dose 2 weeks before gonadotropin treatment.
  3. 03HumanObservational studyEfficacy outcome

    In women with PCOS, added triptorelin was linked to fewer miscarriages after IVF than gonadotropins alone.

    In plain wordsIn women with PCOS, added triptorelin was linked to fewer miscarriages after IVF than gonadotropins alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseMiscarriage after IVF
    Study

    n: not reported in source

    Comparator
    Gonadotropins alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg single doseAs given in this study (human).

    Measurements

    Miscarriage rate
    18.2%
    with GnRH agonist
    Miscarriage rate
    38.5%
    without GnRH agonist

    Source sentences

    Summary
    Miscarriage rates after treatment in ovulation induction with (16.7%) and without GnRH-a (39.4%) and in IVF with (18.2%) and without GnRH-a (38.5%) were almost identical and were therefore analyzed together.
    2 context sentences
    Summary · context
    Retrospective analysis of the outcome of 97 pregnancies according to the treatment protocol, with or without GnRH-a.
    Summary · context
    Gonadotropin-releasing hormone agonist (Decapeptyl, D-Trp6, microcapsules, 3.75 mg) was given in a single dose 2 weeks before gonadotropin treatment.
  4. 04HumanObservational studyEfficacy outcome

    In women with PCOS, added triptorelin was linked to higher cumulative livebirth rates after four cycles than gonadotropins alone.

    In plain wordsIn women with PCOS, added triptorelin was linked to higher cumulative livebirth rates after four cycles than gonadotropins alone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseCumulative livebirth after four cycles
    Study

    n: not reported in source

    Comparator
    Gonadotropins alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg single doseAs given in this study (human).

    Measurements

    Cumulative livebirth rate
    64%
    with GnRH agonist
    Cumulative livebirth rate
    26%
    gonadotropins alone

    Source sentences

    Summary
    Cumulative livebirth rate after four cycles for GnRH-a was 64% compared with 26% for gonadotropins only.
    2 context sentences
    Summary · context
    Retrospective analysis of the outcome of 97 pregnancies according to the treatment protocol, with or without GnRH-a.
    Summary · context
    Gonadotropin-releasing hormone agonist (Decapeptyl, D-Trp6, microcapsules, 3.75 mg) was given in a single dose 2 weeks before gonadotropin treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.